capAI PLC - Interim Results
capAI plc
(the "Company" and, together with its subsidiaries, the "Group" or "capAI")
Interim Results for the six-month period ended
capAI plc (LSE: CPAI) is pleased to announce its unaudited interim results for the six-month period ended
Enquiries
Company:
capAI plc hello@capaiplc.com
Broker:
AlbR Capital Limited Tel: +44 (0) 207 469 0930
Chairman's Statement
The six-month period ended
Capital Structure
On
In
In
Author42 - Soft Launch
On
Movie42 (formerly Creator42) - MVP Achieved During the Period
On
capMedical - New Division
On
In
Board Changes
On
Summary
We end the period with Author42 completing a successful public beta, a new division underway, US market access, a simplified capital structure, and a strengthened Board. capAI operates a capital-efficient venture model, securing access to AI technologies through licence and option agreements with R42 Group, enabling the Group to evaluate multiple opportunities while retaining option-based exposure to successful projects. I continue to draw no salary, with my remuneration aligned exclusively to long-term equity value creation for shareholders. I am grateful to all shareholders, partners and advisers for their continued support and look forward to reporting further progress.
Principal Risks and Uncertainties
As at
Key risks for the remainder of the financial year include:
Strategic and Execution Risk: Delivery of the Group's AI strategy depends on identifying and developing quality opportunities, structuring ventures effectively, and scaling efficiently. Operational complexity and disciplined execution remain central priorities.
Key Personnel Risk: The Group's progress is closely tied to its small senior team, particularly
Funding and Market Risk: While the Group had sufficient resources at the period end, this position was further strengthened post period-end through the receipt of proceeds from a placing and the exercise of warrants. The Board is on record as being disciplined and measured in its approach to dilution, seeking to balance funding needs with shareholder value. Nonetheless, future funding may be required to support the growth of projects. The Group recognises that investor sentiment and broader economic conditions may influence access to capital.
Regulatory and Related Party Risk: The Company is subject to the
Currency Risk: The Group is exposed to foreign currency risk, primarily in US dollars, arising from its US subsidiaries (capMedia Inc and capMedical Inc) and activities conducted in
Going Concern: The Board considers it appropriate to adopt the going concern basis, while remaining mindful of future delivery milestones and capital planning.
Financial Risk: Liquidity was managed conservatively to support operations and strategic objectives.
Financial Review
The loss before taxation for the six-month period ended
Administrative expenses of
Cash and cash equivalents as at
The Directors remain confident in the Group's ability to continue as a going concern, supported by successful fundraisings and ongoing strategic developments.
Directors
The Directors of the Company during the period ended
Professor
Related Party Disclosures
Details of Director participation in fundraisings, share option grants, and related party transactions are disclosed in the Chairman's Statement and are further explained in the notes to the interim financial statements.
Directors' Responsibility Statement
The Directors confirm to the best of their knowledge:
· the interim financial statements have been prepared in accordance with International Accounting Standard 34, Interim Financial Reporting, as adopted in the
· the interim financial statements give a true and fair view of the assets and liabilities, financial position and loss of the Group;
· the Interim Report includes a fair review of the information required by DTR 4.2.7R, being an indication of important events that have occurred during the first six months of the financial year and their impact on the interim financial information, and a fair description of the principal risks and uncertainties for the remaining six months of the year; and
· the interim financial information includes a fair review of the information required by DTR 4.2.8R, being the information required on related party transactions.
Subsequent Events
Since the period-end, several significant developments have taken place in the development of the Group's applied AI venture platform.
On
On
On
On
Outlook
The Board is confident in the Group's strategic direction and its ability to deliver meaningful long-term value for shareholders. The Group is progressing its focused strategy of disciplined execution, capital efficiency and the selective advancement of high-potential AI opportunities, supported by its licence and option partnership with R42.
The Group's core philosophy is to grow the business through capital-efficient AI ventures while seeking to minimise dilution for shareholders. The Company secures access to technologies through option-based agreements, enabling evaluation of multiple opportunities without committing significant capital upfront.
The Board extends its sincere thanks to shareholders, partners and advisers for their continued support and belief in the Group's vision.
We look forward to the journey ahead as the Board remains focused on executing the Group's strategic vision.
On behalf of the Board
Professor
Executive Chairman
Consolidated Condensed Statement of Comprehensive Income
For the six-month period ended
|
|
Note |
Group Unaudited Six-month period ended 31 March 2026 £ |
Group Unaudited Six-monthperiod ended 31 March 2025 £ |
Group Audited Year ended £ |
|
Continuing operations
|
|
|
|
|
|
Administrative expenses |
|
(968,791) |
(137,062) |
(791,432) |
|
|
|
|
|
|
|
Operating loss |
|
(968,791) |
(137,062) |
(791,432) |
|
|
|
|
|
|
|
Interest receivable |
|
885 |
116 |
903 |
|
Write-back of loans and debts |
|
- |
- |
- |
|
|
|
|
|
|
|
(Loss)/profit before taxation |
|
(967,906) |
(136,946) |
(790,529) |
|
|
|
|
|
|
|
Taxation |
|
- |
- |
- |
|
|
|
|
|
|
|
(Loss)/profit for the period from continuing operations |
|
(967,906) |
(136,946) |
(790,529) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Total comprehensive (loss)/income for the period |
|
(967,906) |
(136,946) |
(790,529) |
|
|
|
|
|
|
|
Total comprehensive (loss)/income for the period attributable to: |
|
|
|
|
|
Equity holders of the company |
|
(967,906) |
(136,946) |
(790,529) |
|
|
|
|
|
|
|
|
|
(967,906) |
(136,946) |
(790,529) |
|
|
|
|
|
|
|
(Loss)/earnings per share attributable to equity owners |
|
|
|
|
|
Continuing operations - basic (pence) |
5 |
(0.251) |
(0.007) |
(0.029) |
|
Continuing operations - diluted (pence) |
5 |
(0.251) |
(0.007) |
(0.029) |
|
|
|
|
|
|
Consolidated Condensed Statement of Financial Position
As at
|
|
Note |
Group Unaudited As at 31 March 2026 £ |
Group Unaudited As at 31 March 2025 £ |
Group Audited As at £ |
|
Assets |
|
|
|
|
|
|
|
|
|
|
|
Non-current assets |
|
|
|
|
|
Investment in subsidiaries |
3 |
- |
- |
- |
|
|
|
|
|
|
|
Current assets |
|
|
|
|
|
Trade and other receivables |
4 |
83,123 |
40,108 |
85,252 |
|
Cash and cash equivalents |
|
120,487 |
101,101 |
96,444 |
|
|
|
|
|
|
|
Total assets |
|
203,610 |
141,209 |
181,696 |
|
|
|
|
|
|
|
Equity and liabilities |
|
|
|
|
|
|
|
|
|
|
|
Equity |
|
|
|
|
|
Share capital |
6 |
1,556,351 |
1,535,375 |
1,551,581 |
|
Share premium |
7 |
3,024,325 |
2,128,673 |
2,676,333 |
|
Share based payments reserve |
8 |
816,356 |
17,334 |
192,606 |
|
Retained deficit |
|
(5,398,208) |
(3,776,719) |
(4,430,302) |
|
|
|
|
|
|
|
|
|
(1,176) |
(95,337) |
(9,782) |
|
Current liabilities |
|
|
|
|
|
Trade and other payables |
9 |
204,786 |
236,546 |
191,478 |
|
|
|
|
|
|
|
Total equity and liabilities |
|
203,610 |
141,209 |
181,696 |
|
|
|
|
|
|
|
Total equity and liabilities attributable to: |
|
|
|
|
|
Equity holders of the company |
|
203,610 |
141,209 |
181,696 |
|
|
|
|
|
|
|
|
|
203,610 |
141,209 |
181,696 |
Consolidated Condensed Statement of Changes in Equity
For the six-month period ended
|
|
Share capital |
Share premium |
Share based payments reserve |
Retained deficit |
Total |
|
|
£ |
£ |
£ |
£ |
£ |
|
|
|
|
|
|
|
|
Balance as at |
1,531,435 |
2,034,113 |
2,960 |
(3,639,773) |
(71,265) |
|
Loss for the period |
- |
- |
- |
(136,946) |
(136,946) |
|
Share based payment |
- |
- |
- |
|
|
|
Total comprehensive income for the period |
- |
- |
- |
(136,946) |
(136,946) |
|
Issue of ordinary shares |
3,940 |
94,560 |
- |
- |
98,500 |
|
Equity settled share-based payments |
- |
- |
14,374 |
- |
14,374 |
|
Total transactions with owners |
3,940 |
94,560 |
14,374 |
- |
112,874 |
|
Balance at |
1,535,375 |
2,128,673 |
17,334 |
(3,776,719) |
(95,337) |
|
Loss for the period |
- |
- |
- |
(653,583) |
(653,583) |
|
Total comprehensive loss for the period |
- |
- |
- |
(653,583) |
(653,583) |
|
Issue of ordinary shares |
16,206 |
547,660 |
- |
- |
563,866 |
|
Equity settled share-based payments |
- |
- |
175,272 |
|
175,272 |
|
Total transactions with owners |
16,206 |
547,660 |
175,272 |
- |
739,138 |
|
Balance as at |
1,551,581 |
2,676,333 |
192,606 |
(4,430,302) |
(9,782) |
|
Loss for the period |
- |
- |
- |
(967,906) |
(967,906) |
|
Share-based payment expense |
- |
- |
623,750 |
- |
623,750 |
|
Total comprehensive loss for the period |
- |
- |
623,750 |
(967,906) |
(344,156) |
|
Issue of ordinary shares |
4,770 |
347,992 |
- |
- |
352,762 |
|
Total transactions with owners |
4,770 |
347,992 |
- |
- |
352,762 |
|
Balance as at |
1,556,351 |
3,024,325 |
816,356 |
(5,398,208) |
(1,176) |
Consolidated Condensed Statement of Cash Flows
For the six-month period ended
|
|
Group Unaudited Six-month period ended 31 March 2026 £ |
Group Unaudited Six-month period ended 31 March 2025 £ |
Group Audited Year ended £ |
|
Operating activities |
|
|
|
|
(Loss)/profit before taxation |
(967,906) |
(136,946) |
(790,529) |
|
Share-based payment expense |
623,750 |
14,374 |
189,646 |
|
Non-cash settlement of fees via share issue |
- |
- |
36,000 |
|
(Increase)/decrease in trade and other receivables |
2,129 |
(9,086) |
(54,230) |
|
Increase/(decrease) in trade and other payables |
13,308 |
105,930 |
60,862 |
|
|
|
|
|
|
Net cash used in operating activities |
(328,719) |
(25,728) |
(558,251) |
|
|
|
|
|
|
Cash flows from financing activities |
|
|
|
|
Proceeds from issue of shares |
352,762 |
98,500 |
574,866 |
|
Loans received |
- |
- |
51,500 |
|
|
|
|
|
|
Net cash generated from financing activities |
352,762 |
98,500 |
626,366 |
|
|
|
|
|
|
Cash flows from investing activities |
|
|
|
|
|
|
|
|
|
Net cash generated from investing activities |
- |
- |
- |
|
|
|
|
|
|
Net increase/(decrease) in cash and cash equivalents in period |
24,043 |
72,772 |
68,115 |
|
Cash and cash equivalents at beginning of period |
96,444 |
28,329 |
28,329 |
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents at end of period |
120,487 |
101,101 |
96,444 |
|
|
|
|
|
Notes to the Unaudited Condensed Interim Financial Statements
For the six-month period ended
1. General information
capAI plc (the "Company") is a public limited company incorporated in
The Company was admitted to the Official List of the Financial Conduct Authority by way of a Standard Listing and to trading on the Main Market of the London Stock Exchange on
The interim report and financial statements for the six-month period ended
The Group's principal activity is the development and commercialisation of artificial intelligence technologies through its strategic framework: Identify, Incubate and Invent. It focuses on sourcing, building and scaling high-efficiency, high-impact ventures, with an initial emphasis on media and medicine, while retaining flexibility to pursue exceptional opportunities across the broader AI, deep tech and longevity landscape.
The Company's registered office is
2. Basis of preparation
These condensed consolidated interim financial statements have been prepared under the historical cost convention, on a going concern basis, and in accordance with International Financial Reporting Standards, International Accounting Standards and IFRIC interpretations as adopted for use in the
The Group's accounting reference date is 30 September. Accordingly, this interim reporting period covers the six months from
Statement of compliance
The interim report includes the condensed consolidated interim financial statements, which have been prepared in accordance with International Accounting Standard 34 'Interim Financial Reporting'. These financial statements should be read in conjunction with the Group's annual financial statements for the year ended
Accounting policies
The accounting policies and methods of computation followed in the preparation of the interim financial statements are consistent with those used in the Group's annual financial statements for the year ended
Going concern
The Directors have assessed the Group's ability to continue as a going concern, taking into account its financial position as at
The Directors believe it is appropriate to prepare these interim financial statements on a going concern basis. While further funding may be required to support the execution and scale-up of the Group's AI strategy, the Board is confident in its ability to secure such funding as and when required. This confidence is underpinned by the Group's strategic repositioning into a high-growth and topical sector, strong shareholder alignment, and the depth of experience within the Board and leadership team, and the Group's established track record of raising capital.
However, the potential requirement for additional capital represents a material uncertainty that may cast significant doubt over the Group's ability to continue as a going concern. Notwithstanding this uncertainty, the Directors are satisfied that the going concern basis remains appropriate.
3. Investment in subsidiaries
|
|
Group Unaudited As At 31 March 2026
|
Group Unaudited As at 31 March 2025
|
Group Audited As at
|
|
|
£ |
£ |
£ |
|
|
|
|
|
|
Investments in subsidiaries |
- |
- |
74 |
Details of subsidiaries
The following subsidiaries were held by the Group during the period ended
capMedia, Inc - Country of incorporation:
capMedia (UK) Ltd - Country of incorporation:
capMedical (UK) Ltd - Country of incorporation:
capMedical, Inc - Country of incorporation:
capMedia (UK) Ltd was formerly known as capAI opportunities Ltd (and before that, Dukemount Limited). capMedical (UK) Ltd was formerly known as DKE Care and Leisure Ltd. Both
4 Trade and other receivables
|
|
Group Unaudited As At 31 March 2026
|
Group Unaudited As at 31 March 2025
|
Group Audited As at
|
|
|
£ |
£ |
£ |
|
|
|
|
|
|
Other receivables, including prepayments |
83,123 |
40,108 |
85,252 |
|
|
|
|
|
|
|
|
|
|
|
|
83,123 |
40,108 |
85,252 |
5. Earnings per share
Basic (loss)/earnings per share is calculated by dividing the total comprehensive (loss)/income attributable to equity holders of the Group by the weighted average number of ordinary shares in issue during the period.
|
|
Group Unaudited As at 31 March 2026
|
Group Unaudited As at 31 March 2025
|
Group Audited As at
|
|
|
£ |
£ |
£ |
|
|
|
|
|
|
(Loss)/profit on continuing operations |
(967,906) |
(136,946) |
(790,529) |
|
|
|
|
|
|
Total comprehensive (loss)/income attributable to equity holders of the Group |
(967,906) |
(136,946) |
(790,529) |
|
|
|
|
|
|
Weighted average number of shares in issue - expressed in thousands |
|
|
|
|
Basic |
385,046 |
2,063,525 |
2,754,776 |
|
Diluted |
385,046 |
2,063,525 |
2,754,776 |
|
|
|
|
|
|
Basic and diluted (loss)/earnings per share |
|
|
|
|
Continuing operations - basic (pence) |
(0.251) |
(0.007) |
(0.0287) |
|
Continuing operations - diluted (pence) |
(0.251) |
(0.007) |
(0.0287) |
Diluted earnings per share for the period ended
As the Group reported a net loss for the six-month period ended
6. Share capital
|
Ordinary shares Allotted, issued and fully paid |
Number of Shares
|
Share Capital |
|
|
Number |
£ |
|
|
|
|
|
As at |
1,719,316,623 |
17,193 |
|
Shares issued |
394,000,000 |
3,940 |
|
As at |
2,113,316,623 |
21,133 |
|
Shares issued |
1,620,614,013 |
16,206 |
|
As at |
3,733,930,636 |
37,339 |
|
Following share consolidation: |
373,393,063 |
37,339 |
|
Shares issued |
47,750,000 |
4,770 |
|
|
|
|
|
As at |
421,143,063 |
42,109 |
On
As a consequence of the share consolidation, the number of options and conditional awards outstanding and their exercise prices were adjusted in accordance with the terms of the relevant option awards. These adjustments were mechanical in nature and did not result in any modification to the fair value of the awards for the purposes of IFRS 2 Share-based Payment.
On
In
|
Deferred shares Allotted, issued and fully paid |
Number of Shares
|
Share Capital
|
|
|
Number |
£ |
|
|
|
|
|
As at |
1,030,940,939 |
1,514,242 |
Both classes of deferred Shares have no voting rights, no entitlement to attend General Meetings of the Company, no right to any dividend or other distribution and will carry only the right to participate in any return of capital to the extent of the amount paid up or credited as paid up on each deferred Share after the holders of existing ordinary shares have received, not only the aggregate amount paid up on those shares, but also
As at
· 61,624,316 deferred shares of
· 969,316,623 deferred shares of
totalling 1,030,940,939 deferred shares with an aggregate nominal value of
|
Ordinary and deferred shares Allotted, issued and fully paid |
Group Unaudited As at 31 March 2026
|
Group Unaudited As at 31 March 2025
|
Group Audited As at
|
|
|
£ |
£ |
£ |
|
|
|
|
|
|
Ordinary shares |
42,109 |
21,133 |
37,339 |
|
Deferred shares |
1,514,242 |
1,514,242 |
1,514,242 |
|
|
|
|
|
|
|
1,556,351 |
1,535,375 |
1,551,581 |
7. Share premium
|
Ordinary shares Allotted, issued and fully paid |
Share Premium |
|
|
£ |
|
|
|
|
As at |
2,034,113 |
|
Shares issued |
94,560 |
|
As at |
2,128,673 |
|
Shares issued |
547,660 |
|
As at |
2,676,333 |
|
Shares issued |
347,992 |
|
|
|
|
As at |
3,024,325 |
8. Share based payments
Warrants
Warrants issued for services provided are accounted for as equity-settled share-based payments under IFRS 2 - Share-Based Payment. These comprise adviser warrants granted in consideration for professional services rendered to the Company. During the period, 757,500 warrants were issued to AlbR Capital Limited, the Company's corporate broker, in connection with the
No warrants were issued to investors pursuant to the
As at
|
|
Number of Warrants
|
|
|
|
|
As at |
801,579,499 |
|
Warrants issued pursuant to placings and fundraisings |
600,000,000 |
|
Warrants issued for services |
18,000,000 |
|
As at |
1,419,579,499 |
|
Warrants issued pursuant to placings and fundraisings |
750,000,000 |
|
Warrants issued for services |
20,625,000 |
|
Warrants exercised during the period |
(612,828,300) |
|
As at |
1,514,876,199 |
|
Share consolidation |
151,487,620 |
|
Warrants issued for services |
757,500 |
|
Warrants exercised during the period |
20,500,000 |
|
|
|
|
As at |
131,745,120 |
Share options
The Company has implemented equity-settled share-based payment arrangements for its directors, accounted for under IFRS 2 - Share-Based Payment. During the period,
Vesting of the options is conditional on achieving specific share price hurdles and maintaining continuous service over defined periods. The fair value of each grant has been determined using the Black-Scholes option pricing model, with the total value expensed over the vesting periods in accordance with IFRS 2.
His retained options are exercisable until
On
As at
|
|
Number of Options |
|
As at |
- |
|
Directors' options (granted on |
50,000,000 |
|
Directors' options (granted on |
187,500,000 |
|
As at |
237,500,000 |
|
Anti-dilution awards granted ( |
49,130,974 |
|
Options lapsed on departure of |
(8,166,667) |
|
Options granted to |
8,166,667 |
|
|
|
|
As at |
286,630,974 |
In accordance with the directors' remuneration arrangements as disclosed in the Company's RNS dated
Fair value measurement
A Black-Scholes model has been used to determine the fair value of both warrants and share options at the respective grant dates. The model incorporates several factors, including:
· the market price of the Company's shares at grant date,
· the exercise price of the instrument,
· expected share price volatility,
· expected life of the option/warrant,
· risk-free interest rate, and
· the expected level of future dividends (assumed nil).
The inputs into the model were as follows:
|
|
Granted on 24 October 2024
|
Granted on 7 April 2025 |
Granted on 9 February 2026 |
|
Warrant life (years) |
2.375 |
1.9 |
1.07 |
|
Risk free rate (%) |
5.00% |
4.50% |
4.50% |
|
Expiry date |
|
|
|
|
Exercise price at grant (£) |
|
|
|
|
Expected volatility (%) |
20% |
185.73% |
20% |
|
Expected dividend yield |
- |
- |
- |
|
Share price at grant (£) |
|
|
|
|
|
Granted on 29 January 2025
|
Granted on 12 March 2025
|
Granted on 4 November 2025
|
Granted on 17 December 2025
|
|
Options life (years) |
3 |
3 |
3 |
3 |
|
Risk free rate (%) |
4.75% |
4.50% |
4.50% |
4.50% |
|
Expiry date |
10 yrs from grant |
10 yrs from grant |
10 yrs from grant |
10 yrs from grant |
|
Exercise price at grant (£) |
|
|
|
|
|
Expected volatility (%) |
20% |
20% |
20% |
20% |
|
Expected dividend yield |
- |
- |
- |
- |
|
Share price at grant (£) |
|
|
|
|
The share options granted on
The Company has applied an expected volatility of 20% in valuing share-based payment arrangements using the Black-Scholes model. This reflects historical share price movement and is considered appropriate for a
Share-based payment expense
The total fair value of equity-settled share-based payment arrangements granted during the period was determined using the Black-Scholes option pricing model, as detailed above.
The following table presents the fair value of the share-based awards granted during the period and the corresponding charge recognised in the income statement:
|
|
Fair Value
|
Charge Six-month period ended 31 March 2026 |
|
|
£ |
£ |
|
|
|
|
|
Directors' options - |
6,469 |
1,075 |
|
Directors' options - |
549,394 |
91,315 |
|
Accelerated vesting on departure of |
145,376 |
114,124 |
|
Anti-dilution awards - Prof |
825,897 |
110,874 |
|
Anti-dilution awards - |
206,474 |
206,474 |
|
Directors' options - |
94,794 |
94,794 |
|
|
5,095 |
5,095 |
|
Total |
|
623,750 |
The fair value of each option was determined using the Black-Scholes model, assuming a three-year option life, consistent with small-cap norms. Although the awards vest in tranches over shorter service milestones and share price performance targets, the Board considers the options to form part of a longer-term incentive plan. Accordingly, the total fair value is recognised on a straight-line basis over a three-year service period, reflecting the substance of the arrangement.
The remainder of the fair value of the share options will be recognised in future periods over the three-year service period, in accordance with the requirements of IFRS 2.
Options granted
Pursuant to the anti-dilution provisions disclosed in the RNS dated
Professor
The share price on
9. Trade and other payables
|
|
Group Unaudited As at 31 March 2026 |
Group Unaudited As at 31 March 2025 |
Group Audited As at |
|
|
£ |
£ |
£ |
|
|
|
|
|
|
Trade and other payables |
172,156 |
89,878 |
33,497 |
|
Other creditors |
3,147 |
117,243 |
9,701 |
|
Accruals |
29,483 |
29,425 |
148,280 |
|
|
|
|
|
|
|
|
|
|
|
|
204,786 |
236,546 |
191,478 |
10. Related Party Transactions
During the period and up to the date of this report, the Group entered into the following related party transactions in accordance with IAS 24:
Directors' participation in fundraisings
The director participation in the
· Professor
·
Professional fees
Included within administrative expenses for the six-month period ended
Included within administrative expenses for the six-month period ended
Management charges
During the period, capAI plc charged capMedical Inc a management fee of
During the period, capAI plc charged capMedia, Inc a management fee of
Following the period end, capAI plc raised an invoice of
11. Events after the Reporting Period
In
In
The New Ordinary Shares will rank pari passu with the existing Ordinary Shares.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE